Selecta Biosciences (SELB) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Selecta Biosciences (SELB) trades at $0.8812 with AI Score 46/100 (Grade C). Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs. Market cap: $135M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for SELB: SELB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SELB against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SELB: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Selecta Biosciences (SELB) Healthcare & Pipeline Overview
Selecta Biosciences is a clinical-stage biopharmaceutical company pioneering nanoparticle immunomodulatory drugs to treat and prevent human diseases. With a focus on gene therapy and biologic therapies, Selecta's lead programs target methylmalonic acidemia (SEL-302) and chronic refractory gout (SEL-212), positioning it within the competitive biotechnology landscape.
What Is the Investment Thesis for SELB?
Selecta Biosciences presents a notable research candidate within the biotechnology sector, driven by its innovative ImmTOR platform and diverse pipeline of immunomodulatory drugs. The Phase III clinical trials for SEL-212 in chronic refractory gout represent a near-term value driver, with positive results potentially leading to regulatory approval and commercialization. Furthermore, the preclinical development of SEL-302 for methylmalonic acidemia and other gene therapy programs offers long-term growth potential. The company's strategic collaborations with major pharmaceutical players validate its technology and provide financial resources for continued development. However, the company's significant negative profit margin of -8550.6% highlights the risks associated with clinical-stage biopharmaceutical companies, including the uncertainty of clinical trial outcomes and regulatory approvals. As of 2026-05-10, investors should carefully weigh the potential rewards against these inherent risks.
Based on FMP financials and quantitative analysis
SELB Key Highlights
Market capitalization of $135M reflects the company's current valuation and investor sentiment.
- SEL-212 is in Phase III clinical trials for the treatment of chronic refractory gout, representing a near-term catalyst.
- SEL-302 is in preclinical stage targeting methylmalonic acidemia, a rare metabolic disorder.
- Profit margin of -8550.6% indicates significant ongoing investment in research and development.
- Beta of 0.83 suggests lower volatility compared to the overall market.
Who Are SELB's Competitors?
SELB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| MDXG MiMedx Group, Inc. | $4.45 | +2.53% | $649M | 90 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SELB's Key Strengths?
Innovative ImmTOR™ technology platform.
- Diverse pipeline of immunomodulatory drugs.
- Strategic collaborations with major pharmaceutical companies.
- Focus on unmet medical needs in genetic and autoimmune diseases.
What Are SELB's Weaknesses?
High operating expenses and negative profit margin.
- Reliance on clinical trial outcomes and regulatory approvals.
- Limited commercialized products.
- Small number of employees for a company with a large pipeline.
What Could Drive SELB Stock Higher?
Data readout from Phase III clinical trials of SEL-212 for chronic refractory gout.
- Initiation of Phase I clinical trials for SEL-302 in methylmalonic acidemia.
- Expansion of strategic partnerships with pharmaceutical companies.
- Advancement of preclinical programs for autoimmune diseases.
What Are the Key Risks for SELB?
Financial-distress signal — its Altman Z-Score of -3.23 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure of SEL-212 in Phase III clinical trials.
- Delays in regulatory approvals for drug candidates.
- Competition from other biotechnology companies.
- High operating expenses and negative profit margin.
- Dependence on strategic partnerships for funding and development.
What Are the Growth Opportunities for SELB?
- Expansion into New Therapeutic Areas: Selecta has the opportunity to leverage its ImmTOR platform to develop therapies for a broader range of autoimmune diseases, such as type 1 diabetes and multiple sclerosis. The market for autoimmune disease treatments is substantial, with a global market size estimated at over $100 billion. By expanding its pipeline to address these unmet needs, Selecta can significantly increase its revenue potential. This expansion is an ongoing process, with new preclinical programs continuously being evaluated.
- Strategic Partnerships and Licensing Agreements: Selecta can further enhance its growth prospects by forging additional strategic partnerships with pharmaceutical companies and research institutions. These collaborations can provide access to new technologies, funding, and expertise, accelerating the development and commercialization of its product candidates. The company's existing partnerships with Takeda and Sarepta demonstrate the value of this approach. The timeline for new partnerships is ongoing, with potential deals being evaluated regularly.
- Advancement of Gene Therapy Programs: Selecta's gene therapy programs, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency, represent a significant growth opportunity. The gene therapy market is projected to experience rapid growth, driven by the potential to provide long-lasting or curative treatments for genetic disorders. Successful clinical development and regulatory approval of these programs could generate substantial revenue for Selecta. The timeline for SEL-302 is preclinical, with Phase 1 trials expected to begin within the next 1-2 years.
- Commercialization of SEL-212: The successful completion of Phase III clinical trials and subsequent commercialization of SEL-212 for chronic refractory gout is a critical growth driver for Selecta. Gout affects millions of people worldwide, and there is a significant unmet need for more effective treatments. Positive clinical trial results and regulatory approval could lead to substantial revenue generation for Selecta. The timeline for potential FDA approval is estimated to be within the next 2-3 years, contingent on positive trial data.
- Development of Tolerogenic Therapies: Selecta's development of tolerogenic therapies for primary biliary cholangitis (PBC) and other autoimmune diseases represents another promising growth avenue. Tolerogenic therapies aim to re-establish immune tolerance, addressing the underlying cause of autoimmune diseases rather than just managing symptoms. The market for these therapies is expected to grow as the understanding of autoimmune disease mechanisms improves. The timeline for these therapies is longer-term, with preclinical and early clinical development expected over the next 3-5 years.
What Threats Does SELB Face?
- Competition from established pharmaceutical companies.
- Uncertainty of clinical trial outcomes.
- Regulatory hurdles and delays.
- Potential for product liability claims.
What Are SELB's Competitive Advantages?
- Proprietary ImmTOR™ technology platform.
- Strong intellectual property portfolio.
- Strategic collaborations with leading pharmaceutical companies.
- Focus on immunomodulation for a range of diseases.
What Does SELB Do?
Selecta Biosciences, Inc., founded in 2007 and headquartered in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing innovative nanoparticle immunomodulatory drugs. The company's core technology platform, ImmTOR™, is designed to promote immune tolerance, addressing a wide range of diseases by modulating the immune system's response. Selecta's initial focus was on mitigating unwanted immune responses to gene therapies and biologic drugs, enabling safer and more effective treatments. Over the years, Selecta has expanded its pipeline to include therapies for autoimmune diseases and other conditions. The company's lead therapeutic gene therapy program, SEL-302, is currently in the preclinical stage and aims to improve the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. Additionally, Selecta is developing biologic therapies, with SEL-212 being the most advanced, currently in Phase III clinical trials for the treatment of chronic refractory gout. Beyond these lead programs, Selecta is also developing product candidates to treat IgA-mediated diseases, such as IgA nephropathy. Selecta has established several strategic collaborations and licensing agreements with prominent pharmaceutical companies and research institutions, including Takeda Pharmaceuticals USA, Inc., Swedish Orphan Biovitrum, Sarepta Therapeutics, Inc., and Asklepios Biopharmaceutical, Inc. These partnerships are crucial for advancing its research and development efforts and expanding the potential applications of its ImmTOR platform.
What Products and Services Does SELB Offer?
- Develop nanoparticle immunomodulatory drugs.
- Research treatments for methylmalonic acidemia (MMA).
- Develop biologic therapies for chronic refractory gout.
- Create product candidates for IgA-mediated diseases.
- Develop gene therapies for ornithine transcarbamylase deficiency.
- Develop tolerogenic therapies for autoimmune diseases.
- Collaborate with pharmaceutical companies and research institutions.
How Does SELB Make Money?
- Develop and license immunomodulatory drug candidates.
- Generate revenue through strategic collaborations and partnerships.
- Advance drug candidates through clinical trials.
- Seek regulatory approval for commercialization of therapies.
What Industry Does SELB Operate In?
Selecta Biosciences operates within the dynamic and competitive biotechnology industry, characterized by rapid innovation and high-risk, high-reward opportunities. The market for immunomodulatory drugs is expanding, driven by the increasing prevalence of autoimmune diseases, genetic disorders, and the growing demand for safer and more effective therapies. Selecta's ImmTOR platform positions it to capitalize on these trends by addressing the challenges of unwanted immune responses to biologic drugs and gene therapies. The company faces competition from established pharmaceutical companies and other biotech firms developing similar immunomodulatory technologies. Success in this industry hinges on clinical trial outcomes, regulatory approvals, and strategic partnerships.
Who Are SELB's Key Customers?
- Patients suffering from genetic disorders like methylmalonic acidemia.
- Patients with chronic refractory gout.
- Pharmaceutical companies seeking innovative drug candidates.
- Research institutions collaborating on drug development.
Company Profile
Selecta Biosciences operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Watertown, US. The company is led by CEO Carsten Brunn. SELB has traded publicly since 2016.
How Selecta Biosciences Is Valued
Selecta Biosciences carries a market capitalization of $135M, placing it in the micro-cap category. Relative to its peer group, SELB's quantitative score of 46/100 is below the peer average of 76/100.
Key Financial Metrics
Return on equity for Selecta Biosciences stands at 139.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -47.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -58.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.48 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Selecta Biosciences's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.23 places it in the distress zone, a signal of elevated financial risk.
SELB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that those closest to the business believe in its potential growth.
- Community sentiment has shifted positively, with increased discussions around Selecta's innovative therapies gaining traction among investors.
- Recent partnerships and collaborations have sparked optimism about the company's ability to expand its market presence and enhance product pipeline.
- Analysts have noted a growing interest in the biotechnology sector, positioning Selecta favorably within a broader bullish trend.
Bear Case
- Concerns over the company's cash runway have surfaced, raising questions about its ability to sustain operations without additional funding.
- Social sentiment shows some volatility, with bearish discussions highlighting skepticism about the effectiveness of Selecta's therapies in clinical trials.
- Recent competition in the biotech space has intensified, leading to worries that Selecta may struggle to differentiate itself from emerging players.
- Market perception remains cautious, with some investors recalling past disappointments in biotech stocks, leading to hesitancy in new investments.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SELB Latest News
No recent news available for SELB.
SELB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SELB.
Price Targets
Wall Street price target analysis for SELB.
SELB MoonshotScore
What does this score mean?
The MoonshotScore rates SELB 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Carsten Brunn
CEO
Carsten Brunn is the CEO of Selecta Biosciences. He brings extensive experience in the pharmaceutical and biotechnology industries. Prior to joining Selecta, he held leadership positions at Bayer, where he oversaw various strategic initiatives and product development programs. He has a proven track record of driving innovation and commercial success in the healthcare sector. Brunn holds advanced degrees in science and business, providing him with a strong foundation for leading a biopharmaceutical company.
Track Record: Under Carsten Brunn's leadership, Selecta Biosciences has focused on advancing its clinical pipeline and expanding its strategic partnerships. Key milestones include the progression of SEL-212 into Phase III clinical trials and the continued development of the ImmTOR platform. He has also overseen the company's efforts to secure funding and strengthen its financial position.
SELB Healthcare Stock FAQ
What does the AI Score mean for SELB?
SELB holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs. Their lead program, SEL-302, targets methylmalonic acidemia, while …
What does Selecta Biosciences, Inc. do?
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs using its ImmTOR platform. The company's primary goal is to address unwanted immune responses to biologic drugs and gene therapies, as well as to develop treatments for autoimmune diseases.
What do analysts say about SELB stock?
Analyst coverage of Selecta Biosciences (SELB) typically focuses on the potential of its ImmTOR platform and the progress of its clinical trials. Key valuation metrics include market capitalization, cash runway, and potential revenue from its lead programs. Growth considerations center on the successful completion of clinical trials, regulatory approvals, and the expansion of its pipeline.
What are the main risks for SELB?
The main risks for Selecta Biosciences include the uncertainty of clinical trial outcomes, particularly for its lead programs SEL-212 and SEL-302. Failure to achieve positive results in these trials could significantly impact the company's valuation and future prospects. Regulatory hurdles and delays in obtaining approvals for its drug candidates also pose a risk.
How does Selecta Biosciences, Inc. navigate regulatory approval processes?
Selecta Biosciences navigates regulatory approval processes by adhering to stringent guidelines set by regulatory agencies such as the FDA and EMA. This involves conducting comprehensive preclinical studies to establish safety and efficacy, followed by well-designed clinical trials to evaluate the drug candidates in human subjects. Selecta maintains open communication with regulatory agencies, seeking guidance and feedback throughout the development process.
What are the key growth opportunities for SELB in healthcare?
Key growth opportunities for Selecta Biosciences lie in expanding its therapeutic focus within the healthcare sector. This includes developing new therapies for autoimmune diseases beyond its current pipeline, exploring applications of its ImmTOR platform in other disease areas, and expanding its geographic reach through partnerships and licensing agreements.
What are the key factors to evaluate for SELB?
Selecta Biosciences (SELB) holds an AI score of 46/100 (low). Selecta Biosciences presents a notable research candidate within the biotechnology sector, driven by its innovative ImmTOR platform and diverse pipeline of immunomodulatory drugs. Not financial advice.
How frequently does SELB data refresh on this page?
SELB's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SELB's recent stock price performance?
Selecta Biosciences (SELB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative ImmTOR™ technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-05-10.
- Clinical trial outcomes are inherently uncertain.
- Analyst opinions may vary.